Biogen Idec and MAKScientific team up on MS drug candidates

MAKScientific, LLC, a privately held company in Boston focused on the discovery of novel therapeutics modulating cannabinoid pathways, today announced that it has entered into an exclusive option and collaboration agreement with Biogen Idec (NASDAQ: BIIB) to develop and commercialize drug candidates for the treatment of multiple sclerosis (MS) and other neurodegenerative diseases.